Your account is not claimed yet. You can sign up with ORCID to claim your account.

Victor Cervera-Carrascon (Víctor Cervera-Carrascón)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 7

Top Venues

Oncoimmunology

Cells

Pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, James H A Clubb, Tatiana Viktorovna Kudling, Saru Basnet, Camilla Heiniö, Susanna Grönberg-Vähä-Koskela, Marjukka Anttila, Riikka Havunen, Anna Kanerva, Akseli E Hemminki
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. Oncoimmunology 11 (1) (2022)
Joao Santos, Camilla Heiniö, Dafne C A Quixabeira, Sadia Zafar, James Clubb, Santeri Pakola, Victor Cervera-Carrascon, Riikka Havunen, Anna Kanerva, Akseli E Hemminki
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells 10 (5) (2021)
Víctor González-Ruiz, Ángel Cores, Olmo Martín-Cámara, Karen Orellana, Victor Cervera-Carrascon, Patrycja Michalska, Ana I Olives, Rafael León, M Antonia Martín, José Carlos Menéndez
Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation. Pharmaceutics 13 (10) (2021)
Riikka Havunen, Riikka Kalliokoski, Mikko Siurala, Suvi Sorsa, João M Santos, Victor Cervera-Carrascon, Marjukka Anttila, Akseli Hemminki
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. Cells 10 (2) (2021)
Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti S Rannikko, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology 9 (1) (2020)
Marta López González, Dinja Oosterhoff, Jelle J Lindenberg, Ioanna Milenova, Sinead M Lougheed, Tania Martiáñez, Henk Dekker, Dafne Carolina Alves Quixabeira, Basav Hangalapura, Jos Joore, Sander R Piersma, Victor Cervera-Carrascon, Joao Manuel Santos, Rik J Scheper, Henk M W Verheul, Connie R Jiménez, Rieneke Van De Ven, Akseli Hemminki, Victor W Van Beusechem, Tanja D De Gruijl
Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. Oncoimmunology 8 (10) (2019)
Sadia Zafar, Suvi Sorsa, Mikko Siurala, Otto Hemminki, Riikka Havunen, Victor Cervera-Carrascon, João Manuel Santos, Hongjie Wang, Andre Lieber, Tanja De Gruijl, Anna Kanerva, Akseli Hemminki
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology 7 (10) (2018)

Victor Cervera-Carrascon.css-eqlu8i{font-size:small;padding-left:4px;} (Víctor Cervera-Carrascón)

Publication Activity (10 Years)

Top Topics

Top Venues

Victor Cervera-Carrascon (Víctor Cervera-Carrascón)